ARV-825, a BRD4 Inhibitor, Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Myeloid Leukemia and Overcomes Stroma Mediated Resistance by Modulating Chemokine Receptor, Cell Adhesion and Metabolic Targets

BRD4, a member of the bromodomain and extra terminal domain (BET) family, is critical in the assembly of a ‘super enhancer complex’ driving expression of oncogenes MYC, SOX2 and NF-KB and anti-apoptotic proteins e.g. Bcl-2 and BCL-XL and validated target in AML therapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research